<DOC>
	<DOCNO>NCT01827735</DOCNO>
	<brief_summary>Type 1 diabetes common severe chronic autoimmune disease worldwide cause autoimmune ( loss self tolerance ) mediate destruction insulin produce pancreatic beta cell thus lead insulin deficiency development hyperglycaemia . Currently , medical management type 1 diabetes focus intensive insulin replacement therapy limit complication ( retinopathy , nephropathy , neuropathy ) ; nevertheless clinical outcome remain sub optimal . There intensive effort design novel immunotherapy arrest autoimmune process thereby preserve residual insulin production lead few complication well clinical outcome . The vast majority gene contribute susceptibility type 1 diabetes find encode protein involve immune regulation function . In particular , several susceptibility protein involve interleukin 2 ( IL-2 ) pathway regulate T cell activation tolerance self antigen . Aldesleukin human recombinant IL-2 product produce recombinant DNA technology use genetically engineer E. coli stain contain analog human interleukin-2 gene . There substantial nonclinical , preclinical clinical data ultra low dose IL-2 ( aldesleukin ) therapy arrest autoimmune mediate destruction pancreatic beta cell induction functional T regulatory cell . However , prior embark large proof concept trial type 1 diabetes essential optimum dose IL-2 ( aldesleukin ) determine . The objective study establish patient type 1 diabetes optimal dose IL-2 ( aldesleukin ) administer order increase T regulatory cell response .</brief_summary>
	<brief_title>Regulatory T Cells Type 1 Diabetes Patients Treated With IL-2</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>Written inform consent Type 1 diabetes 1850 year Duration diabetes less 24 month diagnosis One positive autoantibody ( antiislet cell , antiGAD , antiIA2 , antiZnT8 ) Hypersensitivity aldesleukin excipients History severe cardiac disease History malignancy within past 5 year ( exception localize carcinoma skin resect cure cervical carcinoma situ ) History concurrent use immunosuppressive agent steroids History unstable diabetes recurrent hypoglycaemia Active autoimmune , hyper hypothyroidism Active clinical infection Major preexist organ dysfunction previous organ allograft Females pregnant , lactate intend get pregnant study Males intend father pregnancy study Donation 500 ml blood within 2 month prior aldesleukin administration Participation previous therapeutic clinical trial within 2 month prior aldesleukin administration Abnormal ECG Abnormal full blood count , chronic renal failure ( Stage 3,4,5 ) and/or evidence impair liver function Positive Hepatitis B surface Antigen ( HBsAg ) Hepatitis C serology Human Immunodeficiency Virus ( HIV ) test Any medical history clinically relevant abnormality deem principal investigator and/or medical monitor make patient ineligible inclusion safety concern</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Interleukin 2</keyword>
	<keyword>Type 1 diabetes</keyword>
	<keyword>T regulatory cell</keyword>
	<keyword>Adaptive trial</keyword>
</DOC>